{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": {
    "pdf_name": "Liu_et_al.__2024_",
    "source_pdf": "data/clinical_files/Liu et al. (2024).pdf",
    "total_pages": 13,
    "total_blocks": 146,
    "total_characters": 36717
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 5,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza",
      "relevance_explanation": "This quote explicitly states that the trial evaluated quadrivalent recombinant influenza vaccine (RIV4, which is Flublok) alongside quadrivalent inactivated egg-based (IIV4) and cell culture-based (ccIIV4) vaccines, confirming that Flublok (quadrivalent) was evaluated in the pivotal trial."
    },
    {
      "id": 2,
      "quote": "Enrolled and Randomized n=723 vaccine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit ... RIV4 in Year 1 n=152",
      "relevance_explanation": "This quote lists the randomized allocation of participants to Fluarix IIV4 (a quadrivalent standard-dose vaccine) and RIV4 (Flublok quadrivalent), directly supporting that Flublok was evaluated against Fluarix in the pivotal trial."
    },
    {
      "id": 3,
      "quote": "sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza",
      "relevance_explanation": "This quote confirms that the study compared the recombinant quadrivalent vaccine (Flublok) with quadrivalent inactivated vaccines, which include Fluarix, thus directly supporting the claim."
    },
    {
      "id": 4,
      "quote": "Fluarix IIV4: Day 0 (n = 24), 1 m (n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0 (n = 40), 1 m (n = 40), 6 m (n = 38).",
      "relevance_explanation": "This quote provides explicit evidence that Flublok (RIV4) and Fluarix (IIV4) were both evaluated in the same trial, with participant numbers given for each group."
    },
    {
      "id": 5,
      "quote": "Fluarix IIV4 18\u221244 years: Day 0 (n = 55), 1 m (n = 55), 6 m (n = 48); ... RIV4 18\u221244 years: Day 0 (n = 99), 1 m (n = 98), 6 m (n = 85); RIV4 45\u221264 years: Day 0 (n = 98), 1 m (n = 98), 6 m (n = 92);",
      "relevance_explanation": "This quote shows that both Fluarix (quadrivalent standard-dose) and Flublok (quadrivalent recombinant) were administered to participants in the pivotal trial, supporting the claim."
    }
  ],
  "model_used": "gpt-4.1"
}